Financial Performance - The company's operating revenue for Q3 2023 was approximately RMB 10.67 billion, representing a year-on-year increase of 0.30%[7] - The net profit attributable to shareholders for the same period was approximately RMB 2.76 billion, reflecting a year-on-year increase of 0.77%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately RMB 2.95 billion, with a significant year-on-year increase of 23.76%[7] - The cash flow from operating activities for the year-to-date period reached approximately RMB 10.32 billion, showing a substantial increase of 33.82% compared to the previous year[7] - The basic earnings per share for Q3 2023 was RMB 0.94, an increase of 1.08% year-on-year[7] - The diluted earnings per share for the same period was also RMB 0.94, reflecting a significant increase of 16.05% year-on-year[7] - The company achieved operating revenue of RMB 29.54 billion in the first three quarters of 2023, representing a year-on-year growth of 4.0%[12] - Total operating revenue for the first three quarters of 2023 reached RMB 29.54 billion, an increase of 4.03% compared to RMB 28.39 billion in the same period of 2022[27] - Net profit for the first three quarters of 2023 was RMB 8.15 billion, representing a growth of 9.43% from RMB 7.45 billion in the same period of 2022[28] - The company reported a total profit of RMB 9.78 billion, an increase of 10.98% compared to RMB 8.82 billion in the same period of 2022[27] - The total comprehensive income for the first three quarters was RMB 7.60 billion, an increase of 13.63% from RMB 6.69 billion in the same period of 2022[30] Revenue Sources - Revenue from American clients reached RMB 19.4 billion, with a year-on-year growth of 36% after excluding COVID-19 commercialization projects[10] - Revenue from the top 20 global pharmaceutical companies reached RMB 11.82 billion, with a strong year-on-year growth of 43% after excluding COVID-19 projects[10] - The company’s revenue from existing clients accounted for nearly 99%, totaling RMB 29.12 billion, with a year-on-year growth of 26% after excluding COVID-19 projects[10] - Revenue from the testing business was RMB 4.85 billion, reflecting a year-on-year increase of 16.2%[14] - WuXi Biology achieved revenue of RMB 1.89 billion, a year-on-year increase of 6.5%, with an adjusted gross margin of 42.8%, up 1.6 percentage points year-on-year[15] - WuXi ATU's cell and gene therapy CTDMO business generated revenue of RMB 1.03 billion, an increase of 11.6% year-on-year, with an adjusted gross margin of -6.1%[16] - The new molecular biology-related revenue in the biology segment grew strongly by 35% year-on-year, contributing 25.9% to the overall biology business revenue[15] Cash Flow and Assets - The cash flow from operating activities increased by 33.82% year-on-year, attributed to stable revenue collection and optimized working capital management[9] - Cash and cash equivalents reached ¥9,448,561,845.32, up from ¥7,985,741,393.85, reflecting a growth of about 18.3%[24] - Total current assets amounted to ¥29,777,189,611.66, an increase of approximately 24.0% from ¥23,997,226,540.21 on December 31, 2022[24] - Total assets as of September 30, 2023, were ¥71,759,281,237.93, compared to ¥64,690,326,746.96 at the end of 2022, indicating a growth of around 10.0%[26] - The company’s cash balance at the end of the third quarter of 2023 was ¥9,446,351,731.41, compared to ¥9,213,956,461.06 at the end of the third quarter of 2022[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 202,845[19] - The company paid dividends amounting to RMB 2,649,084 thousand in 2023, which is an increase of 73.4% compared to RMB 1,529,442 thousand in 2022[39] Future Outlook - The company expects significant growth in TIDES business revenue in Q4 2023, projected to exceed 60% for the full year[13] - The company anticipates that revenue from non-COVID commercial production projects in Q4 2023 will exceed RMB 10 billion for the first time[18] - Excluding COVID-related projects, the company expects Q4 revenue growth of 29-34% and a full-year revenue increase of 25-26%[18] - The adjusted gross margin for the full year 2023 is projected to be between 41.7% and 42.1%, with net profit expected to exceed RMB 10 billion for the first time[18] - The company has adjusted its 2023 revenue growth forecast from 5-7% to 2-3% due to lower-than-expected demand in early drug development stages[18] Employee Information - The company employed a total of 41,148 staff, with 12,877 holding a master's degree or above, and 1,400 holding a doctoral degree or equivalent[5] - The company continues to focus on talent retention through recruitment, training, promotion, and incentives to maintain high service standards and industry leadership[5]

Financial Performance - Revenue for the first half of 2023 reached RMB 18,871.3 million, representing a 6.3% increase from RMB 17,756.3 million in the same period of 2022[8]. - Gross profit increased by 17.6% to RMB 7,555.7 million, with a gross margin of 40.0%, up from 36.2% in the previous year[8]. - Net profit attributable to shareholders rose by 14.6% to RMB 5,313.1 million, with a net profit margin of 28.2%, compared to 26.1% in 2022[8]. - Adjusted net profit attributable to shareholders was RMB 5,094.7 million, an 18.5% increase from RMB 4,300.7 million in the prior year[8]. - The company achieved revenue of RMB 18,871.3 million, a year-on-year increase of 6.3%, and net profit attributable to shareholders of RMB 5,313.1 million, up 14.6% year-on-year[9]. - The company reported a basic earnings per share of RMB 1.81, reflecting a 13.8% increase from RMB 1.59 in the same period last year[8]. - The adjusted basic earnings per share was RMB 1.73, an increase of 17.7% from RMB 1.47 in the previous year[8]. - Net profit for the period increased by 14.6% to RMB 5,356.9 million, with a net profit margin rising from 26.3% to 28.4%[24]. - The total comprehensive income for the period attributable to equity holders was RMB 4,806,967 thousand, an increase of 10.7% from RMB 4,342,460 thousand in the prior year[194]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 69,319.1 million, a 7.2% increase from RMB 64,690.3 million at the end of 2022[8]. - Total liabilities increased by 7.6% to RMB 19,120.4 million, compared to RMB 17,763.7 million in the previous year[8]. - Cash and cash equivalents rose by 20.1% to RMB 9,585.0 million, up from RMB 7,983.9 million at the end of 2022[8]. - The debt-to-asset ratio remained stable at 27.6%, slightly up from 27.5% at the end of 2022[8]. - As of June 30, 2023, total assets amounted to RMB 41,739,069 thousand, an increase from RMB 40,693,101 thousand as of December 31, 2022, representing a growth of approximately 2.57%[195]. - The company's net equity as of June 30, 2023, was RMB 50,198,782 thousand, compared to RMB 46,926,673 thousand at the end of 2022, marking an increase of around 4.83%[196]. - The total liabilities decreased from RMB 14,499,361 thousand to RMB 16,363,159 thousand, indicating a rise of approximately 12.87%[195]. Revenue Sources and Client Growth - The company added over 600 new clients in the first half of 2023, with active clients exceeding 6,000 over the past 12 months, leading to a 25% year-on-year increase in orders excluding COVID-19 commercialization projects[9]. - Revenue from U.S. clients reached RMB 12.37 billion, a 42% year-on-year increase when excluding COVID-19 projects; revenue from European clients was RMB 2.22 billion, up 19%[9]. - The WuXi Chemistry segment generated revenue of RMB 13,467.2 million, a 3.8% increase year-on-year, with a strong growth of 36.1% when excluding COVID-19 projects[10]. - The WuXi Testing segment reported revenue of RMB 3,091.0 million, an 18.7% year-on-year increase, with laboratory analysis and testing services contributing RMB 2,250 million, up 18.8%[12]. - The WuXi Biology segment achieved revenue of RMB 1,232.6 million, a 13.0% increase year-on-year, with new molecular-related revenue growing by 51%[13]. - The company’s D&M (Development and Manufacturing) revenue reached RMB 9.67 billion, a 2.1% increase year-on-year, with a strong growth of 54.5% when excluding COVID-19 projects[11]. - Approximately 99% of the company’s revenue came from existing clients, totaling RMB 18.65 billion, a 30% year-on-year increase when excluding COVID-19 projects[9]. Operational Efficiency and Cost Management - The net cash flow from operating activities for the six months ended June 30, 2023, was RMB 5,340.7 million, an increase of 41.7% compared to RMB 3,767.9 million for the same period in 2022, driven by stable revenue collection and optimized working capital management[25]. - The net cash used in investing activities for the six months ended June 30, 2023, was RMB 1,307.8 million, a decrease of 65.3% from RMB 3,770.1 million in the same period of 2022, primarily due to timing differences in project settlements leading to reduced capital expenditures[26]. - The net cash used in financing activities for the six months ended June 30, 2023, was RMB 2,612.8 million, an increase of 129.7% compared to RMB 1,137.6 million for the same period in 2022, mainly due to increased cash dividend payments during the reporting period[27]. - The company reported a decrease in cash outflow for the purchase of property, plant, and equipment to RMB 2,296,036 thousand in 2023 from RMB 4,359,857 thousand in 2022, indicating improved capital efficiency[199]. Research and Development - Research and development expenses for the period were RMB 667,045 thousand, slightly up from RMB 657,200 thousand in the previous year[193]. - The company is developing multiple potential FIC/BIC molecules for various cancers, with the first clinical trial application for the brain tumor probe BR-02 accepted by CDE and the BR-11 tumor treatment drug set to start IIT clinical trials in Q3 2023[41]. - The company is committed to leveraging cutting-edge technologies, such as medical big data and automated laboratories, to enhance operational efficiency and reduce drug development barriers[44]. Shareholder and Incentive Plans - The company has established a share incentive plan in place to motivate and retain employees[181]. - The 2022 profit distribution plan was approved, with a cash dividend of RMB 8.9266 per 10 shares to shareholders listed on June 13, 2023[52]. - The board approved the 2023 H-share incentive trust plan on April 24, 2023, to enhance the company's compensation policy[164]. - The company aims to enhance its long-term incentive mechanism to attract and retain talent, ensuring sustainable development[116]. Market Outlook and Strategic Goals - The global pharmaceutical market is expected to continue growing due to economic development, population growth, aging, increased healthcare spending, and rising health awareness[60]. - The demand for pharmaceutical R&D services is anticipated to grow rapidly as large pharmaceutical companies increase outsourcing and small to medium-sized companies seek integrated R&D services[60]. - The company aims to become a leading platform in the global pharmaceutical industry, providing comprehensive and integrated drug R&D and production services[61]. - In 2023, the company will focus on building capabilities and scale, enhancing its integrated enabling platform to support innovation for clients[62]. Risks and Challenges - The pharmaceutical R&D services industry is highly regulated, and any failure to adapt to changes in industry policies and regulations could have a negative impact on the company's operations[70]. - The company faces intensified competition in the global pharmaceutical R&D services market, particularly from large pharmaceutical companies and specialized CRO/CDMO institutions, which may possess stronger financial and technical capabilities[71]. - The loss of core technical personnel poses a risk to the company's competitive advantage and ongoing profitability, particularly if compensation and incentive mechanisms are not competitive[74].

Financial Performance - The company achieved revenue of RMB 18,871.3 million for the six months ended June 30, 2023, representing a year-on-year growth of 6.3%[4] - Net profit attributable to the parent company was RMB 5,313.1 million, an increase of 14.6% compared to the same period in 2022[4] - The adjusted net profit attributable to the parent company was RMB 5,094.7 million, reflecting an 18.5% year-on-year growth[4] - The company achieved a gross profit of RMB 7.56 billion, representing a year-on-year increase of 17.6%, with a gross margin of 40.0%[15] - The total comprehensive income for the period was RMB 4,843,228 thousand, compared to RMB 4,377,071 thousand in the same period of 2022, reflecting an increase of approximately 10.6%[90] - The company reported a significant increase in tax payable to RMB 819.1 million, up 58.2% due to increased taxable profits from subsidiaries during the reporting period[34] - The company reported a significant increase in accounts receivable and other receivables, which rose to RMB 9,237,398 thousand from RMB 7,590,361 thousand, reflecting an increase of about 21.7%[91] Revenue Breakdown - Revenue from U.S. clients reached RMB 12.37 billion, a 42% increase year-on-year when excluding COVID-19 commercialization projects[4] - Revenue from the top 20 global pharmaceutical companies was RMB 7.14 billion, showing a strong growth of 47% when excluding COVID-19 commercialization projects[5] - The WuXi Chemistry segment generated revenue of RMB 13,467.2 million, a 3.8% increase year-on-year[6] - The WuXi Testing segment reported revenue of RMB 3,091.0 million, reflecting an 18.7% year-on-year growth[8] - The TIDES business revenue reached RMB 1.33 billion, with a year-on-year growth of 37.9%[7] - Clinical CRO and SMO achieved revenue of RMB 850 million, a year-on-year increase of 18.3%, with SMO business revenue growing by 34.3%[9] - The biology segment generated revenue of RMB 1.23 billion, reflecting a year-on-year growth of 13.0%, with new molecular-related revenue increasing by 51%[10] Client Growth and Market Presence - The company added over 600 new clients in the first half of 2023, with active clients exceeding 6,000 over the past 12 months[4] - The company’s services to the top 20 global pharmaceutical companies accounted for approximately 38% of total revenue during the reporting period[47] - The early discovery platform contributed over 20% of new customers in the first half of 2023, serving over 1,600 clients with a compound library exceeding 90 billion molecules[10] Financial Position and Cash Flow - Net cash generated from operating activities was RMB 5,340.7 million for the six months ended June 30, 2023, an increase of 41.7% compared to RMB 3,767.9 million for the same period in 2022[23] - Net cash used in investing activities decreased by 65.3% to RMB 1,307.8 million for the six months ended June 30, 2023, primarily due to timing differences in capital expenditures[24] - Total liabilities as of June 30, 2023, were RMB 19,120.4 million, up from RMB 17,763.7 million as of December 31, 2022[25] - The company's total borrowings amounted to RMB 4,422.1 million as of June 30, 2023, all of which were fixed-rate borrowings[26] - The debt-to-asset ratio as of June 30, 2023, was 27.6%, compared to 27.5% as of December 31, 2022, indicating a stable and healthy financial position[27] Strategic Investments and R&D - The company is preparing for the commercialization of CAR-T products, with production expected to start in the first half of 2024[11] - The company aims to enhance its service capabilities in new molecular types such as PROTAC, oligonucleotide drugs, and peptide drugs, to seize new business opportunities[44] - The company is committed to continuous investment in global capabilities and scale to empower pharmaceutical innovation[43] - The company continues to focus on research and development in small molecule drugs, cell therapy, and gene therapy, positioning itself for future growth in these sectors[93] Risks and Challenges - The company recognizes potential risks from declining demand in the pharmaceutical R&D service market, which could negatively impact business if outsourcing trends slow down[70] - The pharmaceutical R&D service industry is highly regulated, with potential adverse impacts on the company's operations if it fails to adapt to changes in industry policies and regulations[71] - The global pharmaceutical R&D service market is becoming increasingly competitive, with threats from both established players and new entrants that may possess stronger financial and technical capabilities[72] - The company's main business revenue is primarily denominated in USD, exposing it to risks from significant appreciation of the RMB, which could increase costs and reduce order volumes[78] Shareholder Information - A total of 131,328 restricted A-shares were released from restrictions under the 2018 A-share incentive plan, accounting for approximately 0.005% of the company's total issued A-shares[49] - The 2022 profit distribution plan was approved, with a cash dividend of RMB 8.9266 per 10 shares for shareholders listed on June 13, 2023[52] - The company completed the redemption of all outstanding zero-coupon convertible bonds amounting to $300 million on April 4, 2023[59] - The board did not recommend any interim dividend for the reporting period[82] Operational Enhancements - The company expanded its testing laboratory by 55,000 square meters during the reporting period, enhancing its capabilities and capacity[46] - The company is focused on enhancing its product offerings through continuous innovation and development of new technologies[132] - The company will maintain the highest international quality standards and continuously improve operational processes to ensure compliance and prevent accidents[66]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD.* 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 2023年第一季度報告 本公告根據香港聯合交易所有限公司證券上市規則第13.09(2)條和第13.10B條及 香港法例第571章《證券及期貨條例》第XIVA部內幕消息條文作出。 下文為無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司統稱「本 集團」或「我們」）2023年財政年度第一季度報告（「2023年第一季度報告」），所載 財務報告根據中國企業會計準則或國際會計準則理事會頒佈的國際財務報告 準則（「國際財務報告準則」）（視情況而定）編製且未經審計。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2023年4月24日 ...

無錫藥明康德新藥開發股份有限公司 WuXi AppTec Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 2359 股份代碼： 年度 報 告 目錄 公司資料 2 董事長報告書 4 財務摘要 5 管理層討論與分析 6 五年統計 47 董事、監事及高級管理層履歷 48 企業管治報告 56 董事會報告 78 獨立核數師報告 129 綜合損益及其他全面收益表 135 綜合財務狀況表 137 綜合權益變動表 139 綜合現金流量表 141 綜合財務報表附註 144 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD.* 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 截至2022年12月31日止年度全年業績公告 財務摘要 2022年 2021年 變化 人民幣百萬元 人民幣百萬元 （百分比除外）（百分比除外） 收入 39,354.8 22,902.4 71.8% 毛利 14,506.5 8,265.5 75.5% 毛利率 36.9% 36.1% 母公司持有者之應佔溢利 8,813.7 5,097.2 72.9% 母公司持有者之應佔溢利淨利率 22.4% 22.3% 經調整非《國際財務報告準則》之 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 2022年第三季度報告 本公告根據香港聯合交易所有限公司證券上市規則第13.09(2)條和第13.10B條及 香港法例第571章《證券及期貨條例》第XIVA部內幕消息條文作出。 下文為無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司統稱「本 集團」）2022年財政年度第三季度報告（「2022年第三季度報告」），所載財務報告 根據中國企業會計準則或國際會計準則理事會頒佈的國際財務報告準則（「國 際財務報告準則」）（視情況而定）編製且未經審計。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2022年10月26日 於本公告日期，本公司董事會包括執行董事李革博士、胡正國先生、楊青博士、陳民章博士、 張朝暉先生及趙寧博士；非執行董事童小 ...

無錫藥明康德新藥開發股份有限公司 WuXi AppTec Co., Ltd.* 股份代碼：2359 （於中華人民共和國註冊成立的股份有限公司） 中期報告 2022 目 錄 公司資料 2 財 務 摘 要 4 管 理 層 討 論 與 分 析 5 法定披露 45 簡明綜合財務報表的審閱報告 85 簡明綜合損益及其他全面收益表 86 簡明綜合財務狀況表 88 簡明綜合權益變動表 90 簡明綜合現金流量表 92 簡明綜合財務報表附註 94 釋義 156 公司資料 | --- | --- | |-------------------------------------------------------------------------------------|-----------------------------------------------| | 董事會 | 審計委員會 | | 執行董事 | 婁賀統博士(主席) | | 李草博士 ( 董 事 長 兼 首 席 執 行 官 ） | 張曉彤先生 蔡江南博士 | | 胡正國先生 | 薪酬與考核委員會 | | (副董事長兼全球首席投資官) 楊 青 博 士 (聯席首席 ...

無錫藥明康德新藥開發股份有限公司 WuXi AppTec Co., Ltd.* 股份代碼：2359 （於中華人民共和國註冊成立的股份有限公司） 年度報告 2021 日 @ ad 目 錄 | --- | --- | |----------------------------|-------| | | | | 公司資料 | 2 | | 董事長報告書 | 4 | | 財務摘要 | 5 | | 管理層討論與分析 | 6 | | 五年統計 | 49 | | 董事、監事及高級管理層履歷 | 50 | | 企業管治報告 | 65 | | 董事會報告 | 83 | | 獨立核數師報告 | 136 | | 綜合損益及其他全面收益表 | 142 | | 綜合財務狀況表 | 144 | | 綜合權益變動表 | 146 | | 綜合現金流量表 | 148 | | 綜合財務報表附註 | 151 | | 釋義 | 305 | 公司資料 | --- | --- | |--------------------------------------------------------------------------------------- ...